KDR (Ab-1175) Antibody

Introduction to KDR/Flk-1 Receptor Tyrosine Kinase

KDR/Flk-1 (Kinase insert Domain Receptor/Fetal liver kinase-1) functions as one of the two primary vascular endothelial growth factor (VEGF) receptors and plays a crucial role in regulating vascular endothelial cell proliferation and differentiation. This receptor tyrosine kinase is activated through autophosphorylation at specific tyrosine residues upon VEGF-A binding, initiating downstream signaling cascades that promote angiogenesis . Understanding the precise molecular mechanisms underlying VEGF-A-induced growth signaling has been essential for developing targeted approaches to modulate angiogenesis in both physiological and pathological conditions .

Research has identified several tyrosine residues within the KDR/Flk-1 structure that become phosphorylated following VEGF-A stimulation. Through comprehensive analysis using site-directed mutagenesis and tryptic peptide mapping, investigators have demonstrated that tyrosine residues Y1175 and Y1214 represent the two major VEGF-A-dependent autophosphorylation sites on KDR/Flk-1 . Among these sites, Y1175 has emerged as particularly significant for endothelial cell proliferation, providing the rationale for developing antibodies specifically targeting this phosphorylation site .

Significance of Y1175 Phosphorylation

The Y1175 phosphorylation creates a specific binding site for the C-terminal SH2 domain of PLC-γ, leading to its activation and subsequent signaling through the PKC-MAP kinase pathway . This mechanism differs from many other receptor tyrosine kinases, which primarily utilize Ras-mediated MAP kinase activation for DNA synthesis, underscoring the unique signaling characteristics of KDR/Flk-1 .

Antibody Generation Strategy

The KDR (Ab-1175) antibody was developed specifically to detect the phosphorylated state of Y1175 on KDR/Flk-1. Researchers generated this antibody by first synthesizing a peptide containing the phosphorylated Y1175 region of KDR/Flk-1 . This phosphopeptide was then used as an antigen to raise antibodies in rabbits, followed by affinity purification to isolate antibodies specifically recognizing the phosphorylated Y1175 region . This approach yielded an antibody with remarkable specificity for the phosphorylated form of KDR/Flk-1 at this critical tyrosine residue .

The production methodology ensured that the resulting antibody would recognize the tertiary structure surrounding the phosphorylated Y1175 site. This specificity is crucial for applications requiring discrimination between the activated and non-activated forms of KDR/Flk-1, as well as for distinguishing KDR/Flk-1 from other receptor tyrosine kinases .

Validation of Antibody Specificity

The specificity of the KDR (Ab-1175) antibody was rigorously validated through several complementary approaches. Initial characterization demonstrated that the antibody specifically recognized the VEGF-A-induced phosphorylation state of various KDR/Flk-1 variants expressed in MSS31 cells, with the notable exception of the Y1175F mutant . This observation confirmed that the antibody specifically targets the phosphorylated Y1175 residue rather than other regions of the receptor .

Further specificity testing revealed that the antibody does not cross-react with other tyrosine kinases known to bind PLC-γ, including epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), and Flt-1 (VEGFR-1) . This high level of specificity makes the antibody particularly valuable for selective detection of activated KDR/Flk-1 in complex biological samples containing multiple receptor tyrosine kinases .

Detection of Activated KDR/Flk-1 in Primary Endothelial Cells

The KDR (Ab-1175) antibody has demonstrated significant utility in detecting activated KDR/Flk-1 in primary endothelial cells. When human umbilical vein endothelial (HUVE) cells or rat sinusoidal endothelial (SE) cells were stimulated with VEGF-A, the antibody clearly recognized autophosphorylated KDR/Flk-1 with a molecular weight of 230 kDa . This observation confirmed that Y1175 on KDR/Flk-1 is rapidly phosphorylated in vivo in primary endothelial cells following VEGF-A stimulation .

Notably, the antibody enables temporal monitoring of KDR/Flk-1 activation in response to VEGF-A. Studies have shown transient staining of plasma membrane and cytoplasm in HUVE cells with the anti-PY1175 antibody after VEGF-A stimulation . Importantly, this staining pattern was not observed following stimulation with other growth factors such as basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF), or epidermal growth factor (EGF), further confirming the specificity of both the antibody and the phosphorylation event for VEGF-A signaling .

Immunodetection Methods

The KDR (Ab-1175) antibody has proven effective in multiple immunodetection methods, making it versatile for various research applications. These methods include:

1. Western blotting: The antibody successfully detects phosphorylated KDR/Flk-1 in cell lysates following VEGF-A stimulation .

2. Immunohistochemistry: The antibody can be used for histological staining to detect activated KDR/Flk-1 in tissue sections, enabling visualization of receptor activation in both physiological and pathological angiogenesis .

3. Immunocytochemistry: Cellular localization of activated KDR/Flk-1 can be monitored using the antibody, providing insights into the spatiotemporal dynamics of receptor activation .

This versatility makes the KDR (Ab-1175) antibody an invaluable tool for researchers investigating VEGF-A signaling and angiogenesis in various experimental contexts .

Blocking Studies and Mechanism Investigations

The KDR (Ab-1175) antibody has been employed in functional studies to elucidate the mechanisms of VEGF-A signaling through KDR/Flk-1. In particular, researchers have utilized this antibody to investigate the association between phosphorylated Y1175 on KDR/Flk-1 and the C-terminal SH2 domain of PLC-γ .

In pull-down assays, the anti-PY1175 antibody completely blocked the VEGF-A-induced association of KDR/Flk-1 with PLC-γ in vitro . Similarly, a phosphopeptide corresponding to the PY1175 region also blocked this interaction, while control antibodies or non-phosphorylated peptides had no effect . These results provided strong evidence that the C-terminal SH2 domain of PLC-γ directly associates with phosphorylated Y1175 on KDR/Flk-1, establishing the molecular basis for signal transduction from activated KDR/Flk-1 to PLC-γ .

Microinjection Studies in Primary Endothelial Cells

One of the most compelling demonstrations of the KDR (Ab-1175) antibody's utility and the functional significance of Y1175 phosphorylation comes from microinjection experiments in primary endothelial cells. Researchers microinjected the anti-PY1175 antibody into rat sinusoidal endothelial cells and assessed the effect on VEGF-A-stimulated DNA synthesis .

The results were striking: cells injected with the anti-PY1175 antibody showed significantly decreased 5-bromo-2′-deoxyuridine (BrdU) uptake compared to cells injected with control rabbit IgG . This observation provided direct evidence that phosphorylation of Y1175 is crucial for VEGF-A-induced stimulation of DNA synthesis in primary endothelial cells . The ability of the antibody to block cellular proliferation when introduced intracellularly highlights both its specificity and the critical role of the phosphorylated Y1175 site in endothelial cell proliferation .

Comparative Specificity Analysis

The KDR (Ab-1175) antibody distinguishes itself from other KDR/Flk-1 antibodies through its exceptional specificity for the phosphorylated Y1175 site. While conventional antibodies against KDR/Flk-1 recognize the receptor regardless of its activation state, the KDR (Ab-1175) antibody selectively binds only to the activated receptor following VEGF-A stimulation . This property allows researchers to specifically monitor receptor activation rather than merely receptor expression .

Furthermore, the antibody does not cross-react with other phosphorylated receptor tyrosine kinases, including those known to activate similar downstream pathways . This specificity is particularly valuable in complex biological systems where multiple receptor tyrosine kinases may be simultaneously active .

Table 1: Specificity of KDR (Ab-1175) Antibody Against Various Tyrosine Kinase Receptors

Target for Anti-angiogenic Therapy

The discovery that Y1175 phosphorylation is critical for endothelial cell proliferation has significant implications for anti-angiogenic therapy development. The highly specific structure surrounding the phosphorylated Y1175 site, as recognized by the KDR (Ab-1175) antibody, represents a potential target for developing compounds that could block this specific interaction .

Researchers have proposed that compounds specifically targeting the phosphorylated Y1175 region might provide more selective anti-angiogenic effects compared to general tyrosine kinase inhibitors . Such specificity could potentially reduce side effects often associated with broader kinase inhibitors. The KDR (Ab-1175) antibody itself, or derivatives based on its binding properties, could serve as templates for developing such targeted therapeutics .

The potential exists for using PY1175-blocking compounds either alone or in combination with KDR/Flk-1 tyrosine kinase inhibitors in anti-angiogenic therapy . This approach might enhance efficacy while minimizing off-target effects common to many protein kinase inhibitors that often cross-react with multiple kinases .

Diagnostic Applications

Beyond its research applications, the KDR (Ab-1175) antibody holds promise for diagnostic purposes. Its ability to specifically detect activated KDR/Flk-1 in histological sections makes it potentially valuable for assessing angiogenic activity in various pathological conditions, including cancer, diabetic retinopathy, and inflammatory disorders where aberrant angiogenesis contributes to disease progression .

The antibody could enable researchers and clinicians to distinguish between tissues with inactive versus actively signaling VEGF receptors, providing insights into disease activity and potentially guiding therapeutic decisions . This application aligns with the growing interest in developing biomarkers that reflect not just the presence of proteins but their activation state in pathological contexts .

Protocol for Antibody Production

The production of KDR (Ab-1175) antibody involved synthesizing a peptide containing the phosphorylated Y1175 residue of KDR/Flk-1 . This phosphopeptide was then conjugated to a carrier protein and used to immunize rabbits . Following the immunization protocol, the antibody was purified through affinity chromatography using the phosphopeptide to isolate antibodies specifically recognizing the phosphorylated Y1175 region .

This purification process was critical for ensuring the high specificity of the resulting antibody. By removing antibodies that might recognize non-phosphorylated epitopes or other regions of the receptor, the affinity purification yielded an antibody preparation with exceptional selectivity for the phosphorylated Y1175 site .

Usage in Various Experimental Techniques

The KDR (Ab-1175) antibody has been successfully employed in various experimental techniques, each requiring specific protocols:

1. Western blotting: For detecting phosphorylated KDR/Flk-1 in cell lysates, the antibody is typically used at optimized dilutions following standard western blotting protocols, with particular attention to preserving phosphorylation status during sample preparation .

2. Immunohistochemistry/Immunocytochemistry: The antibody can be used for staining fixed cells or tissue sections to visualize the spatial distribution of activated KDR/Flk-1 .

3. Blocking experiments: The antibody can be used in competitive binding assays to block interactions between phosphorylated KDR/Flk-1 and its binding partners .

4. Microinjection studies: The antibody can be introduced into living cells through microinjection to assess the functional consequences of blocking the phosphorylated Y1175 site .

Signal Transduction Cascade

The phosphorylation of Y1175 on KDR/Flk-1 represents a critical event in VEGF-A signal transduction. Following VEGF-A binding to KDR/Flk-1, the receptor dimerizes and undergoes autophosphorylation at multiple tyrosine residues, including Y1175 . The phosphorylated Y1175 creates a specific binding site for the C-terminal SH2 domain of PLC-γ .

Upon binding to phosphorylated Y1175, PLC-γ becomes activated and catalyzes the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) to generate inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) . These second messengers trigger calcium release from intracellular stores and activate protein kinase C (PKC), respectively . Activated PKC then initiates the MAP kinase pathway, leading to endothelial cell proliferation .

This PLC-γ–PKC–MAP kinase pathway appears to be the predominant mechanism through which KDR/Flk-1 stimulates endothelial cell proliferation, distinguishing it from many other growth factor receptors that primarily utilize the Ras-mediated MAP kinase pathway . The KDR (Ab-1175) antibody has been instrumental in elucidating this signaling mechanism by enabling specific detection and functional analysis of the phosphorylated Y1175 site .